Professor Johannes Schetelig joins us to discuss the results of the ASAP phase 3 trial comparing remission induction with immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00065-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Professor Banu Aygun joins us to discuss the REACH trial testing hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00078-4?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr Sabine Braat and Dr Katherine Fielding join us to discuss their study presenting new haemoglobin thresholds for defining anaemia.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00030-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Doctor Elisabeth Schorb joins us to discuss the MARTA phase 2 trial, treating older, fit patients with primary diffuse large B-cell CNS lymphoma with high-dose chemotherapy and autologous stem-cell transplantation.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00371-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Professor Stephan Ehl joins us to discuss a prospective observational study on paediatric autoimmune lymphoproliferative immunodeficiencies.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr Susan O'Brien joins Lan-Lan Smith to discuss results of the phase 3 PREVAPIX-ALL trial, which compares direct oral anticoagulant apixaban to low-molecular-weight-heparin for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00314-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Professor Enrico Lopriore joins us to discuss a trial testing darbepoetin alfa to prevent postnatal anaemia in infants with haemolytic disease of the fetus and newborn.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00285-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Professor Meletios Dimopoulos joins us to discuss two trials for patients with relapsed and refractory multiple myeloma - the first report of the DREAMM-3 phase 3 and long-term follow-up of the APOLLO phase 3 trial.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00243-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr Eric Ohuma joins us to tell us about a study recently published in The Lancet Haematology on the association between maternal haemoglobin concentrations and maternal and neonatal outcomes.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00170-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Professor Margaret Ragni joins us to discuss the VWDMin study, published in The Lancet Haematology. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA. Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00119-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhaeContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Dr Odejide and Dr Kuczmarski tell us about a study recently published in The Lancet Haematology on the effect of pre-existing mental health conditions on survival in patients with diffuse large B-cell lymphoma.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00094-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae

Professor Alok Srivastava tells us about two clinical trials being published in The Lancet and The Lancet Haematology on a new siRNA therapy called fitusiran for patients with haemophilia A and B.Read the two trials:Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH)https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00284-2/fulltext?dgcid=buzzsprout_icw_podcast_buzzsprout_generalFitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A/B)https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00037-6/fulltext?dgcid=buzzsprout_icw_podcast_buzzsprout_general

Dr Emmanuela E Ambrose tells us about the SPHERE trial on hydroxyurea dose escalation for primary stroke prevention in children with sickle cell disease in TanzaniaRead the full article:Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE)

Dr Sumit Gupta discusses how racial and ethnic disparities affect survival outcomes of children and young adults with acute lymphocytic leukaemia.Read the full article:Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia

Professor Xiao-Jun Huang discusses this Lancet Haematology series on Cellular Therapy in China, covering the history, current research challenges, and future of HSCT and CAR T-cell therapies in China.Read the Series papers:Cellular therapy in China

Dr Glenn Pierce discusses the World Federation of Hemophilia’s Humanitarian Aid Program which provides access to haemophilia care in low-income and lower-middle-income countries.Read the full Review:Achieving access to haemophilia care in low-income and lower-middle-income countries

Dr Amy DeZern discusses the link between myelodysplastic syndrome and autoimmune disorders and the need for a multidisciplinary approach for the treatment of patients who have both.Read the full article:Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?

Dr Nicholas Crombie and Professor Gavin Perkins discuss their randomised phase 3 trial in which they investigated resuscitation with blood products compared with saline in patients with trauma-related haemorrhagic shock receiving prehospital care. 

Dr Fredrik Schjesvold discusses the results of the OCEAN phase 3 trial testing melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide. Read the full article:Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN)

Dr Jacob D Soumerai and Prof Andrew D Zelenetz discuss their phase 2 trial of the BOVen regimen and MRD-driven treatment discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00307-0/fulltext 

Dr Raul Cordoba discusses the joint Series between The Lancet Healthy Longevity and The Lancet Haematology on haematological malignancies in older people.Read the full article:A comprehensive approach to therapy of haematological malignancies in older patients

Professor Obiageli Nnodu and Dr Dennis Chao join acting Deputy Editor Emma Cookson to talk about their new study describing modelling of child mortality as a result of sickle cell disease in Nigeria. Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00191-5/fulltext

Senior Assistant Editor Ben Burwood speaks with Dr Zuguo Mei (Division of Nutrition, Physical Activity, and Obesity, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA)  and Dr Gary M Brittenham (Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY, USA) about their work defining physiologically based serum ferritin thresholds for iron deficiency.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00168-X/fulltext

To mark International Nurses Day, Eugenia Trigoso Arjona, nurse coordinator at Hospital La Fe (Valencia, Spain) and chair of the European Society for Blood and Marrow Transplantation Nurses Global Education Committee, joins acting Editor-in-Chief Yaiza del Pozo Martin to discuss how nurses can reshape the future of haematological care. 

Para el Día International de la Enfermera, Eugenia Trigoso Arjona, enfermera coordinadora en el Hospital La Fe (Valencia, España) y presidenta del comité de educación de la European Society for Blood and Marrow Transplantation Nurses hablo con la Editora Yaiza del Pozo Martin sobre como las enfermeras pueden remodelar el futuro de la hematología. 

A/Prof Nada Hamad (St Vincent’s hospital, Sydney, Australia) joins Editor-in-Chief Dr Lan-Lan Smith to discuss inclusion and diversity in haematology-oncology and transplantation.  

Editor-in-Chief, Dr Lan-Lan Smith, speaks with Dr Judith Boer (Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands) about outcome of ABL-class acute lymphoblastic leukaemia in children in the pre-tyrosine kinase inhibitor era.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30353-7/fulltext

Andrea Biondi joins The Lancet Haematology to discuss his work on imatinib as a treatment for paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Prashant Hiwarkar joins The Lancet Haematology to discuss his new paper, an investigation into whether serial faecal PCR monitoring can predict the risk of adenoviraemia and survival outcomes after HSCT.

Lead author Gita Thanarajasingam joins The Lancet Haematology to discuss the new Commission on assessment and adverse event reporting in haematological malignancies.

Jules Heuberger talks about his study on the effectiveness of EPO use by cyclists.

Petra Innerhofer discusses reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma.

Audrey Bonaventure discusses her CONCORD-2 study, monitoring survival trends of two types of childhood leukaemia in 53 countries between 1995 and 2009.

Jan Beyer discusses the SURPRISE trial of patients developing complications from superficial-vein thrombosis.

Dr Jose Leal discusses a study of the costs related to malignant and non-malignant blood disorders in Europe in 2012.

David Fajgenbaum discusses a literature review to raise awareness of idiopathic multicentric Castleman disease, a poorly understood haematological disorder.

Walter Ageno discusses the use of an algorithm combining limited and whole-leg compression ultrasonography to diagnose deep-vein thrombosis.

Scott Huntington discusses the financial toxicity of oncology treatments

James Bussel discusses a study looking at treatment options for children facing idiopathic thrombocytopenic purpura.

Klervi Leuraud discusses a study reporting on the risk of developing leukaemia and lymphoma in workers monitored for radiation exposure.

Páll Önundarson describes a new method for monitoring clotting in patients treated with warfarin, which they tested in a non-inferiority, randomised clinical trial.

Mahmoud Zureik discusses risk of bleeding in patients with non-valvular atrial fibrillation who switched and those who remained on a vitamin K antagonist.

Dietger Niederwieser and Richard Lane discuss the journey to 1 million haematopoietic stem cell transplantations.

Guillermo Garcia-Manero discusses a phase 1/2 study on sequential azacitidine and lenalidomide in high-risk MDS and AML.

Gregory Kato discusses a phase I study for the treatment of leg ulcers for people with sickle-cell disease.